Epicardial versus microcirculatory dissociation

European Heart Journal

Volumn 23, Issue 4, 2002, Pages 274-276

  Brener, S J ^a   Topol, E J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST;

ANGIOCARDIOGRAPHY; CLINICAL EXAMINATION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; EDITORIAL; EPICARDIUM; HUMAN; MICROCIRCULATION; MICROEMBOLISM; MUSCLE NECROSIS; PRIORITY JOURNAL; REVASCULARIZATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD FLOW VELOCITY; CORONARY CIRCULATION; CORONARY RESTENOSIS; EMBOLISM; HUMANS; MICROCIRCULATION; MYOCARDIAL REVASCULARIZATION; STENTS; TREATMENT OUTCOME;

EID: 0036487153     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2829     Document Type: Editorial

References (11)

1. Nishida T, Di Mario C, Kern MJ et al. Impact of final coronary flow velocity reserve on late outcome following stent implantation. Eur Heart J 2002; 23: 331-40, doi:10.1053/euhj.2001.2734
2. Topol EJ, Mark DB, Lincoff AM et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999; 354: 2019-24.
3. Herrmann J, Haude M, Lerman A et al. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Circulation 2001; 103: 2339-45.
4. Serruys PW, de Bruyne B, Carlier S et al. Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group. Circulation 2000; 102: 2930-7.
5. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35: 922-8.
6. Biasucci LM, Liuzzo G, Angiolillo DJ, Sperti G, Maseri A. Inflammation and acute coronary syndromes. Herz 2000; 25: 108-12.
7. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 83: IV3-14.
8. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1420-6.
9. Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schomig A, Gawaz M. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001; 37: 1323-8.
10. Lincoff AM, Kereiakes DJ, Macelli MA et al. Abciximab suppresses the rise in plasma levels of inflammatory markers following PTCA. Circulation 2001; 104: 163-7.
11. Walter DH, Fichtlscherer S, Britten MB et al. Initiation of statin therapy immediately after stent implantation: Profound benefit in patients with acute coronary syndromes (Abstr). Circulation 2000: P244.